Drug development is aiming to move from managing disease to correcting it through RNA and gene-editing therapies. But ...
Sarepta Therapeutics Inc.'s bid for the full Federal Circuit’s review of a revived gene-therapy patent dispute with RegenxBio ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results